Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation

Drugs

Volumn 54, Issue 2, 1997, Pages 312-330

  Foster, Rachel H ^a   Wilde, Michelle I ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; IBUTILIDE FUMARATE; POTASSIUM ION; PROCAINAMIDE; SODIUM ION; SOTALOL;

CARDIOVERSION; CLINICAL TRIAL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; POTASSIUM CURRENT; REVIEW; SINUS RHYTHM; SODIUM CURRENT;

EID: 0030810893     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754020-00010     Document Type: Review

References (58)

1. Lip GYH, Watson RDS, Singh SP. Drugs for atrial fibrillation. BMJ 1995 Dec 16; 311: 1631-4
2. Gill MA, Noguchi JK. Cardiac Arrhythmias. In: Herfindal ET. Gourley DR, Lloyd Hart L, editors. Clinical pharmacy and therapeutics. 4th ed. Baltimore: Williams & Wilkins. 1988: 426-55
3. McNeil JJ, Sloman JG. Cardiovascular diseases. In: Speight TM, editor. Avery's drug treatment. 3rd ed. Auckland: Adis Press, 1987: 591-675
4. Wood MA, Clemo HS. Ellenbogen KA. Ibutilide fumarate: a new class III agent for termination of atrial fibrillation and atrial flutter. Expert Opin Invest Drug 1996 Nov; 5: 1511-22
5. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992 Jul: 262: 99-108
6. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide. dsotalol, E-4031. sematilide and dofetilide. Eur J Pharmacol 1993 Mar 30: 234: 43-53
7. Kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995 Mar 15; 91: 1799-806
8. Kr and effects on myocardial refractoriness for class III antiarrhythmic agents, J Cardiovasc Pharmacol 1995 Feb; 25: 336-40
9. Lee KS, Gibson JK. Unique ionic mechanism of action of ibutilide on freshly isolated heart cells [letter]. Circulation 1995 Nov 1; 92: 2755-6
10. Yang T, Snyders DJ. Roden DM. Unique ionic mechanism of action of ibutilide on freshly isolated heart cells. Reply [letter]. Circulation 1995 Nov 1; 92: 2756-7
11. McKay MC, Sykes JS, Lee KS. Effects of U-70226E, a novel antiarrhythmic drug, on the action potential parameters of isolated guinea pig ventricular myocytes [abstract P44]. J Mol Cell Cardiol 1990; 22 Suppl. 1: S15
12. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate. a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992 Nov 3; 222: 93-8
13. Buchanan LV, Lemay RJ, Walters RR, et al. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophys 1996 Feb; 7: 113-9
14. Buchanan LV, Kabell G, Gibson JK. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J Cardiovasc Pharmacol 1995 Apr; 25: 539-44
15. Buchanan LV, Turcotte UM, Kabell GG, et al. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993 Jul; 22: 10-4
16. Buchanan LV, LeMay R, Gibson JK. Comparison of the class III agents d,l sotalol HCI and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effects [abstract]. Pace 1996 Apr; 19(Pt II): 687
17. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential hut a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990 Feb; 81 (2): 686-90
18. Buchanan LV, Kabell G, Brunden MN, et al. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993 Oct; 220: 540-9
19. Buchanan LV, Kabell GG, Gibson JK. Comparison of class III agents in a canine model of proarrhythmia [abstract]. J Am Coll Cardiol 1993 Feb; 21 Suppl. A: 248A
20. Jungbluth GL, VanderLugt JT, Welshman IR. Relationship between subject age and QTc interval prolongation induced by the class III antiarrhythmic drug ibutilide [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 164
21. VanderLugt JT, Gaylor SK, Wakefield LK, et al. Effects of ibutilide fumarate, a new class III antiarrhythmic agent in man [abstract]. Clin Pharmacol Ther 1991 Feb; 49: 188
22. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996 Jul; 28: 130-6
23. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996 Oct 1; 94: 1613-21
24. Jungbluth GL, VanderLugt JT, Kabell GG, et al. The pharmacokinetics and pharmacodynamics of ibutilide fumarate after intravenous infusions in healthy volunteers [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S-211
25. Corvert™ Injection (ibutilide fumarate) - comprehensive review. Kalamazoo (MI): Pharmacia & Upjohn. Feb 1996. (Data on file)
26. Stambler BS, Wood MA, Belz MK, et al. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: enhanced efficacy of ibutilide a new class III antiarrhythmic drug [abstract]. Circulation 1993 Oct: 88 Suppl. (Pt 2): 445
27. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996 May 1; 77: 960-6
28. Guo GB-F, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996 Apr: 27: 1083-9
29. Smith MP, Humphrey SJ, Walters RR, et al. The cardiovascular effects of acute intravenous ibutilide and its D- and L-stereoisomers in conscious beagle dogs [abstract]. Pharmacologist 1991; 33 (3): 170
30. Jungbluth GL, Della-Coletta AA. VanderLugt JT. Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers [abstract]. Pharm Res 1991 Oct; 8 Suppl.: S-249
31. Nabih MA, Prcevski P, Fromm BS, et al. Effect of ibutilide. a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pace Pacing Clin Electrophysiol 1993 Oct; 16: 1975-83
32. Pharmacia & Upjohn Inc. Corvert™ prescribing information. Kalamazoo (MI), 1996
33. Sotalol comparator study (protocol 0019). Corvert™ Injection (ibutilide fumarate) - comprehensive review. Appendix I. Kalamazoo (MI): Pharmacia & Upjohn. Feb 1996. (Data on fils)
34. Volgman AS, Stambler BS, Kappagoda C, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]. Pace 1996 Apr; 19(Pt 11): 608
35. Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990 May: 119 (5): 996-1001
36. Geraets DR, Kienzle MG, Atrial fibrillation and atrial flutter. Clin Pharm 1993 Oct; 12: 721-35
37. News from the 46th Annual Scientific Sessions of the American College of Cardiology. Anaheim (CA). March 1997. Ibutilide for arrhythmia termination after cardiac surgery. Inpharma 1997 Apr 12: (1082): 12
38. Waldo AL. An approach to therapy of supraventricular tachyarrhythmius: an algorithm versus individualized therapy. Clin Cardiol 1994 Sep: 17 Suppl. 11: II-21-6
39. Asplund K, Beermann B, Bergfeldt L, et al. Treatment of atrial fibrillation. Recommendations from a workshop arranged by the Medical Products Agency (Uppsala. Sweden) and the Swedish Society of Cardiology. Eur Heart J 1993 Oct: 14: 1427-33
40. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995 Oct; 108 Suppl.: 352-9
41. Procainamide comparator study (protocol 0021 ). Corvert™ Injection (ibutilide fumarate) - comprehensive review. Appendix I. Kalamazoo (MI): Pharmacia & Upjohn, Feb 1996. (Data on file)
42. Sotalol comparator study (protocol 0019). Pharmacia & Upjohn, Inc. Kalamazoo (MI). 1997 (Data on file)
43. Corvert™ Injection. Pharmacia & Upjohn, Inc. Kalamazoo (MI), 1997. (Data on file)
44. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy 1997: 17 (1): 1-9
45. Feinberg WM, Blackshear JL. Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995 Mar 13; 155: 469-73
46. Bialy D, Lehmann MH, Schumacher DN, et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation [abstract]. J Am Coll Cardiol 1992 Mar 1; 19 (3 Suppl. A): 41A
47. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994 Sep: 48: 145-71
48. Lip GYH. Cardioversion of atrial fibrillation. Postgrad Med J 1995 Aug: 71: 457-65
49. Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol 1997 May 1; 79: 1198-202
50. Lundström T, Rydén L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988: 223: 53-9
51. Singh BN. Acute conversion of atrial fibrillation and flutter: direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 1997 Feb: 29 (2): 391-3
52. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 Aug 10: 321: 406-12
53. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties,and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43 (1): 69-110
54. Fitton A, Sorkin EM. Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 1493 Oct; 46: 678-719
55. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994 Jan; 9: 12-22
56. Cavusoglu E, Frishman WH. Sotalol: a new β-adrenergic blocker for ventricular arrhythmias. Prog Cardiovasc Dis 1995 May-Jun; 37: 423-40
57. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993 Aug 26: 72: 44B-9B
58. Zarkin GA, Bala MV, Calingaert B, et al. Cost-effectiveness of a stepped treatment regimen of ibutilide followed by electrical cardioversion in the treatment of atrial fibrillation and flutter [abstract CD2]. Am J Manage Care 1997 Mar; 3 (3 Suppl.): S43